Industry Partner News: Sarepta Shares Quarterly Update

Sarepta.jpg

This quarterly update contains news regarding Sarepta's clearance from the U.S. Food and Drug Administration (FDA) to start three clinical trials in individuals with DMD – two in gene therapy and one for SRP-5051, its PPMO exon 51 skipping candidate. Sarepta also shares its pursuit of a CRISPR/Cas9 approach through a recently signed collaboration agreement with Duke University. For additional details and more news from Sarepta, please view their newsletter by clicking here.